CR11412A - Inhibidores de cinesina como productos terapeuticos para el cancer - Google Patents

Inhibidores de cinesina como productos terapeuticos para el cancer

Info

Publication number
CR11412A
CR11412A CR11412A CR11412A CR11412A CR 11412 A CR11412 A CR 11412A CR 11412 A CR11412 A CR 11412A CR 11412 A CR11412 A CR 11412A CR 11412 A CR11412 A CR 11412A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
cinesine
cancer
therapeutic products
ksp
Prior art date
Application number
CR11412A
Other languages
English (en)
Inventor
Tinya Abrams
Paul Barsanti
David Duhl
Michel Faure
Paul A Renhowe
Annette Olga Walter
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40328566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11412(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR11412A publication Critical patent/CR11412A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion proporciona novedosos compuestos de imidazol que inhiben la actividad de la proteina de huso de cinesina (KSP, tambien denominada como Eg5). Los inhibidores de KSP pueden reducir la proliferacion celular indeseada, y proporcionan otros efectos terapeuticos.
CR11412A 2007-12-14 2010-05-05 Inhibidores de cinesina como productos terapeuticos para el cancer CR11412A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1396607P 2007-12-14 2007-12-14

Publications (1)

Publication Number Publication Date
CR11412A true CR11412A (es) 2010-06-30

Family

ID=40328566

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11412A CR11412A (es) 2007-12-14 2010-05-05 Inhibidores de cinesina como productos terapeuticos para el cancer

Country Status (30)

Country Link
US (2) US8252832B2 (es)
EP (1) EP2229170B1 (es)
JP (1) JP5501976B2 (es)
KR (1) KR20100098394A (es)
CN (1) CN101939005B (es)
AR (1) AR069676A1 (es)
AU (1) AU2008337570B2 (es)
BR (1) BRPI0821248A2 (es)
CA (1) CA2708822A1 (es)
CL (1) CL2008003707A1 (es)
CO (1) CO6290651A2 (es)
CR (1) CR11412A (es)
DO (1) DOP2010000175A (es)
EA (1) EA018014B1 (es)
EC (1) ECSP10010248A (es)
ES (1) ES2459442T3 (es)
GE (1) GEP20125647B (es)
GT (1) GT201000172A (es)
IL (1) IL205831A0 (es)
MA (1) MA31872B1 (es)
MY (1) MY150214A (es)
NI (1) NI201000091A (es)
NZ (1) NZ585142A (es)
PA (1) PA8807801A1 (es)
PE (1) PE20091451A1 (es)
SM (1) SMP201000095B (es)
TN (1) TN2010000204A1 (es)
TW (1) TW200930704A (es)
UY (1) UY31532A1 (es)
WO (1) WO2009077448A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
CN103153970A (zh) * 2010-04-15 2013-06-12 诺瓦提斯公司 作为ksp抑制剂的*唑和噻唑化合物
JP2016516035A (ja) * 2013-03-15 2016-06-02 ノバルティス アーゲー 細胞増殖阻害剤およびそれらのコンジュゲート
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
JP6971858B2 (ja) * 2015-06-22 2021-11-24 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂性基を有する抗体薬物複合体（ａｄｃ）および抗体プロドラッグ複合体（ａｐｄｃ）
CN105418527A (zh) * 2015-12-28 2016-03-23 青岛友诚高新技术有限公司 一种具有抗乳腺导管癌活性的化合物及其制备方法、用途
CN105646361B (zh) * 2016-02-17 2017-12-01 吉首大学 一种2,4,5‑三芳基咪唑型化合物及其制法和用途
US11660351B2 (en) 2016-12-21 2023-05-30 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
GB201706162D0 (en) * 2017-04-19 2017-05-31 Nat Univ Singapore Compounds
WO2019196111A1 (zh) * 2018-04-13 2019-10-17 上海交通大学医学院附属瑞金医院 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN111529526B (zh) * 2020-04-14 2021-04-23 广州领晟医疗科技有限公司 一种化合物在制备治疗急性胰腺炎的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2409345T3 (es) * 2004-06-18 2013-06-26 Novartis Ag Derivados y compuestos relacionados de N-(1- (1-bencil-4-fenil-1h-imidazol-2-il)-2,2-dimetilpropil)benzamida como inhibidores de la proteína quinesina de huso (KSP) para el tratamiento del cáncer
US7271271B2 (en) 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
MY147188A (en) 2005-08-09 2012-11-14 Novartis Ag Substituted imidazole compounds as ksp inhibitors
CA2674318A1 (en) 2007-01-05 2008-07-17 Novartis Ag Cyclized derivatives as eg-5 inhibitors

Also Published As

Publication number Publication date
WO2009077448A1 (en) 2009-06-25
GT201000172A (es) 2012-04-30
CL2008003707A1 (es) 2009-06-05
US20130012560A1 (en) 2013-01-10
UY31532A1 (es) 2009-08-03
US20090239922A1 (en) 2009-09-24
MA31872B1 (fr) 2010-11-01
CN101939005A (zh) 2011-01-05
EP2229170A1 (en) 2010-09-22
EA018014B1 (ru) 2013-04-30
CA2708822A1 (en) 2009-06-25
ES2459442T3 (es) 2014-05-09
DOP2010000175A (es) 2010-06-30
IL205831A0 (en) 2010-11-30
AU2008337570B2 (en) 2012-04-05
GEP20125647B (en) 2012-09-25
NZ585142A (en) 2012-03-30
ECSP10010248A (es) 2010-07-30
KR20100098394A (ko) 2010-09-06
CN101939005B (zh) 2015-12-16
TN2010000204A1 (en) 2011-11-11
US8252832B2 (en) 2012-08-28
PA8807801A1 (es) 2009-07-23
EA201000900A1 (ru) 2011-02-28
AU2008337570A1 (en) 2009-06-25
AR069676A1 (es) 2010-02-10
US8664256B2 (en) 2014-03-04
NI201000091A (es) 2011-03-15
JP2011506402A (ja) 2011-03-03
JP5501976B2 (ja) 2014-05-28
TW200930704A (en) 2009-07-16
EP2229170B1 (en) 2014-01-22
SMAP201000095A (it) 2010-09-10
BRPI0821248A2 (pt) 2015-06-16
CO6290651A2 (es) 2011-06-20
SMP201000095B (it) 2011-09-09
PE20091451A1 (es) 2009-10-19
MY150214A (en) 2013-12-13

Similar Documents

Publication Publication Date Title
CR11412A (es) Inhibidores de cinesina como productos terapeuticos para el cancer
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
CL2009000687A1 (es) Compuestos derivados de heterociclos nitrogenados de imidazol, inhibidores de la actividad de cinasa raf; composicion farmaceutica; utiles para el tratamiento del cancer, tal como carcinoma de pulmon, pancreatico, de prostata, tiroides, entre otras.
CO6761389A2 (es) Inhibidores de nampt y rock
DOP2010000057A (es) Imidazoles fusionados para el tratamiento del cancer
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
ECSP12012140A (es) Compuestos de para la inhibición de inmunoproteasomas
CL2013000935A1 (es) Compuestos derivados de bencimidazol o sus sales, como inhibidores de cinasa pi3; composicion farmaceutica que los comprende; y su uso para el tratamiento de un neoplasma deficiente en pten seleccionado entre gliomas de cerebro, cancer de mama, cancer de prostata, cancer gastrico y mieloma multiple, entre otros.
HN2009001165A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
CL2008001074A1 (es) Uso de compuestos de triazol, antagonistas de smo para tratar cancer.
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
CU20110159A7 (es) Pirimidinas fusionadas
GT201400090A (es) 2-tiopirimidinonas
BR112014012479A2 (pt) derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas das agonistas de receptor 2 de canabinóide
ECSP10010389A (es) Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa
CO6761294A2 (es) Derivados de pirazol que modulan la estearoil-coa-desaturasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)